Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ: EXAS )

44.37 +1.33 (+3.09%)
Streaming Delayed Price Updated: 1:28 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know
SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last... 
Via Benzinga
Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 10 Years
Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.54%. Currently, Exact Sciences has a market... 
Via Benzinga
Non-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 Guidance
Via Benzinga
Earnings Scheduled For April 26, 2022
Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million. 
Via Benzinga
Preview: Exact Sciences's Earnings
Exact Sciences (NASDAQ:EXAS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Exact... 
Via Benzinga
Analyst Ratings for Exact Sciences
Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings: 
Via Benzinga
Earnings Scheduled For February 22, 2022
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
Via Benzinga
Here's How Much $1000 Invested In Exact Sciences 20 Years Ago Would Be Worth Today
Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 20 years by 2.83% on an annualized basis producing an average annual return of 10.04%. Currently, Exact Sciences has a market... 
Via Benzinga
How do Biotechnology Funds and ETFs Perform Over Five Years?
Biotech investing can be difficult for short-term traders but can offer good returns over five years if balanced with other healthcare positions like the XLV. 
Via Talk Markets
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much
Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 5 years by 12.08% on an annualized basis. Buying $100 In EXAS: 5 years ago, an investor could have... 
Via Benzinga
Tesla, Coinbase, Exact Sciences And More: How Cathie Wood's Top 10 Bets Are Faring In 2022 So Far
Popular stockpicker Cathie Wood-led Ark Investment Management’s top ten key bets — spread across clean energy, innovation, tech, healthcare, and space... 
Via Benzinga
Where Exact Sciences Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ:EXAS) stock. These analysts are typically employed by large Wall Street banks and tasked... 
Via Benzinga
Exact Sciences Clocks 16% Jump In Q4 Non-COVID-19 Revenues
Exact Sciences Corp's (NASDAQ: EXAS) Q4 revenues increased 2% Y/Y to $473.8 million and beat the average Wall Street estimate of $449 million. Excluding COVID-... 
Via Benzinga
4 Big Ark Innovation Components Report Earnings This Week: Could It Spell More Danger For Cathie Wood?
The Ark Funds ETFs have been hit hard in 2022 with growth stocks among the laggards as investors turned to value stocks. Many stockholders have begun to question ... 
Via Benzinga
Exact Sciences: Q4 Earnings Insights
Exact Sciences (NASDAQ:EXAS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
A Preview Of Exact Sciences's Earnings
Exact Sciences (NASDAQ:EXAS) is set to give its latest quarterly earnings report on Tuesday, 2022-02-22. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
How Have Cathie Wood's Top 10 Investments Performed In The Last 6 Months?
Cathie Wood's ARK Invest ETFs are some of the hottest funds after 2020's huge stock market gains. The ARK Innovation ETF (NYSE: ARKK) grew more than 152% in 2020,... 
Via Benzinga
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials... 
Via FinancialNewsMedia
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at... 
Via FinancialNewsMedia
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t... 
Via Benzinga
Why Exact Sciences Share Are Falling Today?
Exact Sciences Corp (NASDAQ: EXAS) has put down $190 million to buy testing laboratory PreventionGenetics, aiming to expand its diagnostics franchise into... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
2 Reasons to Buy Exact Sciences Stock, and 1 Reason to Sell
Its positioning in cancer diagnostics is good, but it faces an important headwind. 
Via The Motley Fool
Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – December 1, 2021 – Early onset colorectal cancer is currently on the rise [[1]], according to a new study [[2]] from the... 
Via FinancialNewsMedia
Exact Sciences Breaks Up With Pfizer -- Time to Buy?
The end of a co-promotion deal with Pfizer could work out well for Exact Sciences. 
Via The Motley Fool
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-... 
Via Benzinga
Exposures Product Safety
Pfizer Will Not Co-Promote Exact Sciences Colorectal Cancer Screening Test
Exact Sciences Corporation (NASDAQ: EXAS) says that Pfizer Inc (NYSE: PFE) will no longer join the Company from November 30 to promote its Cologuard colorectal... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.